EXHIBIT 10.4(b)
SECOND AMENDMENT TO LICENSE AGREEMENT
This Second Amendment to the License Agreement (the "Second
Amendment"), made and entered into this 26th day of June, 2003, is by and
between IMMUNEREGEN BIOSCIENCES, INC., a Delaware corporation with its principal
offices at 8665 E. Via De Ventura Boulevard, Suite E155, Scottsdale, Arizona
85268 (the "Company") on the one hand, and Mark L. Witten, Ph.d., an individual
having his principal address at 7032 East Rosewood Street, Tucson, Arizona 85710
("Witten") and David Harris, Ph.d., an individual having his principal address
at 4110 N. Alvernon Way, Tucson, Arizona 85718 ("Harris"), on the other hand
(Witten and Harris are together the "Licensors").
RECITALS:
WHEREAS, Company and Licensors are parties to a certain License
Agreement, dated as of December 16, 2002 and as may be amended from time to time
(the "License Agreement");
WHEREAS, Company and Licensors entered into First Amendment to License
Agreement whereby Licensors agreed to provide updated information for Schedule
A, "License Proprietary Rights" regarding the docket number, status, application
numbers, grant numbers and grant date for each patent listed, as such
information becomes available (the "First Amendment").
WHEREAS, Company and Licensors desire to amend the License Agreement as
hereinafter set forth;
NOW THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto agree as
follows:
Schedule A, as updated with the information provided herein and
attached hereto, shall supercede that certain Schedule A as previously
contained in the License Agreement.
This Second Amendment may be executed in any number of counterparts,
each of which shall be an original, but all of which together shall constitute
one instrument. A copy of this Second Amendment that is signed and delivered by
telecopy or other facsimile transmission shall be considered an original,
executed Second Amendment.
IN WITNESS WHEREOF, the parties have executed this Second Amendment to
the License Agreement as of the date first above written.
"LICENSORS"
/S/ MARK L. WITTEN, PHD
--------------------------------------------
Mark L. Witten, Ph.d.
/S/ DAVID T. HARRIS, PHD
--------------------------------------------
David Harris, Ph.d.
IMMUNEREGEN BIOSCIENCES, INC.
By: /S/ MICHAEL WILHELM
---------------------------------------
Name: Michael Wilhelm
Title: President
SCHEDULE A
Licensed Proprietary Rights
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
Docket No. Country Title Status Application No. Filing Date Grant No. Grant Date
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
00003 U.S. Amelioration of effects Filed 60/406036 08/27/02
of cigarette
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
00004 U.S. Inducing Hair Growth Filed 60/433996 12/18/02
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
00005 U.S. Acute Respiratory Filed 60/462316 04/14/03
Distress Syndrome
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
00006 U.S. Acute Respiratory Filed 60/465266 04/25/03
Syndromes
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
05299 U.S. Substance P treatment Granted 60/022063* 07/23/96* 5944508 08/31/99
for cancer
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
73958 U.S. Substance P treatment Granted 08/829445+ 03/28/97+ 5998376 12/07/99
for immunocompromised
individuals
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
78273 AU Substance P treatment Granted 4064/97 07/08/97 73721 06/29/01
(acceptance)
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
78274 CA Substance P treatment Filed 2261885 07/08/97
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
78275 EP Substance P treatment Filed 979380490 07/08/97
- ------------- ----------- -------------------------- ---------- --------------- ------------ ----------- --------------
UPDATED JUNE 26, 2003.
- -----------------------
* With respect this patent (Grant No. 5,944,508, Granted 08/31/99), the
Application No. and Filing Date as stated in this Schedule A is obtained
from the official U.S. Patent Claim, which ImmuneRegen (Zara Foster)
provided us on June 23, 2003. The Application No. and Filing Date as
stated in the original Schedule A of the License Agreement (Application
No. 08/829445, Filing Date 03/28/97) did not match the U.S. Patent Claim.
Please advise which Application No. and Filing Date are correct for this
patent.
+ With respect this patent (Grant No. 5,998,376, Granted 12/07/99), the
Application No. and Filing Date as stated in this Schedule A is obtained
from the official U.S. Patent Claim, which ImmuneRegen has supplied to us.
The Application No. and Filing Date as stated in the original Schedule A
of the License Agreement (Application No. 09/028003, Filing Date 02/23/98)
did not match the U.S. Patent Claim. Please advise which Application No.
and Filing Date are correct for this patent.